HENDERSON, NV / ACCESSWIRE / February 13, 2019 / One you should research right away, BioRestorative Therapies, Inc. (BRTX), a life sciences company focused on stem cell-based therapies, is developing a therapy ''ThermoStem'' using brown adipose (fat) derived stem cells to generate brown adipose tissue. The company traded above $3 dollars last year before hitting lows with the rest of the biotech industry. The company has started to rally in lockstep with the industry's ETF: IBB and could be on the verge of a breakout that may send BRTX above their 2018 highs. Get a jumpstart on the crowd by researching BRTX today.
Today we are highlighting: BioRestorative Therapies, Inc. (BRTX), GW Pharmaceuticals plc (NASDAQ: GWPH), CorMedix, Inc. (NYSE: CRMD), Histogenics Corporation (HSGX), and Aurora Cannabis Inc. (NYSE: ACB).
According to Grand View Research, the global obesity treatment market was valued at $3.9 billion in 2015 and is expected to reach $15.6 billion by 2024. According to the Institute of Health Metrics and Evaluation, about 30% of the global population is either obese or overweight. These are just a couple making companies developing weight management solutions so valuable to investors.
One of the more novel approaches to fighting this obesity epidemic is being developed by BioRestorative Therapies, Inc. (BRTX) (Market Cap: $9.769M, Share Price: $0.74), a life sciences company focused on stem cell-based therapies, developing a therapy ''ThermoStem'' using brown adipose (fat) derived stem cells to generate brown adipose tissue (''BAT''). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans.
BRTX just received a Notice of Allowance on the company's fourth patent for their metabolic ThermoStem program. The company's patents span the US, Australia, and Japan.
Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels. This is a very promising sign for the company.
_____
GW Pharmaceuticals plc (GWPH) (Market Cap: $4.772B, Share Price: $147.53), a biopharmaceutical company focused on discovering, developing and commercializing treatment options from its proprietary cannabinoid platform, recently presented at the JP Morgan healthcare conference.
_____
CorMedix, Inc. (CRMD) (Market Cap: $279.072M, Share Price: $2.65) announced the topline results of the full data set of the Company's Phase 3 LOCK-IT-100 study for Neutrolin® as a catheter lock solution in hemodialysis patients. The Company recently announced the topline results from the interim analysis of the study, which was terminated in August 2018 following the recommendation of the independent Data Safety Monitoring Board (DSMB) because efficacy had been demonstrated and the pre-specified level of statistical significance had been achieved.
_____
Histogenics Corporation (HSGX) (Market Cap: $8.063M, Share Price: $0.13), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, just provided an update on the NeoCart regulatory pathway based on its ongoing dialogue with the U.S. Food and Drug Administration (the FDA). Since the initial Type C meeting in October 2018, Histogenics and the FDA have continued their discussions on the clinical data generated to date, the potential need for any additional supplemental clinical data (which may include longer-term data from the ongoing Phase 3 trial or additional studies) and potential alternative regulatory pathways for the NeoCart Biologics License Application (BLA).
_____
Aurora Cannabis Inc. (ACB) (Market Cap: $7.073B, Share Price: $7.17) recently reported revenue rising to $29.9 million in the second quarter to Dec. 29, up 40% from the prior quarter. Proforma revenue, which includes revenue from pending acquisitions, came to $49.5 million.
Legal Disclaimer:
This article was written by Regal Consulting, LLC (''Regal Consulting''). Regal Consulting has agreed to receive a $90,000 convertible note with the issuer for 90 days of service dated 7/10/18. Regal Consulting has signed an amendment to the agreement dated 7/10/18, to extend the agreement and provide additional services for an additional $80,000 convertible note with the issuer. Regal Consulting has signed a second amendment to add additional services for an additional $90,000 convertible note. Regal Consulting has been compensated $50,000 cash for February services. All payments were made directly by BioRestorative Therapies, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspecultors.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. BRTX was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority and does not provide or claim to provide investment advice.
http://www.regalconsultingllc.com/full legal disclaimer/
Microspeculators.com Full Legal Disclaimer Click Here.
Contact Information:
Company Name: Microcap Speculators
Contact Person: Media Manager
Email: [email protected]
Phone: 1-702-720-6310
Country: United States
Website: http://microcapspeculators.com/
SOURCE: ACR Communication, LLC